Ovarian Health After Immunotherapy for Breast Cancer
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This study looks at how a newer cancer treatment (immunotherapy combined with hormone injections) affects ovarian health and fertility in young women with triple-negative breast cancer. It may help doctors better protect fertility during cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18–42 years old
- You have early-stage triple-negative breast cancer (a specific type of breast cancer)
- You have not received chemotherapy or immunotherapy before
- Your cancer treatment plan includes both immunotherapy (a PD-L1 inhibitor drug) and a hormone injection called GnRH agonist to protect your ovaries
- You still have both your ovaries and have not had ovarian radiation therapy
- You are willing to provide written consent and complete study assessments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This study looks at how psychological factors and the immune system affect treatment response in women with triple-negative breast cancer. Researchers will use questionnaires and biological samples to understand these links.
Hear when a new Triple Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.